

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7357055

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	LOXO ONCOLOGY, INC.	05/25/2022
	ELI LILLY AND COMPANY	05/25/2022
	SCHRÖDINGER, LLC	05/24/2022
RECEIVING PARTY DATA		
Name:	PETRA PHARMA CORPORATION	
Street Address:	450 E. 29TH STREET	
Internal Address:	SUITE 506	
City:	NEW YORK	
State/Country:	NEW YORK	
Postal Code:	10016	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	17825680	
CORRESPONDENCE DATA		
Fax Number:	(317)276-3861	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	patents@lilly.com	
Correspondent Name:	ELI LILLY AND COMPANY	
Address Line 1:	P. O. BOX 6288	
Address Line 2:	PATENT DIVISION	
Address Line 4:	INDIANAPOLIS, INDIANA 46206-6288	
ATTORNEY DOCKET NUMBER:	X23034	
NAME OF SUBMITTER:	PATRICIA FOOR	
SIGNATURE:	/Patricia Foor/	
DATE SIGNED:	05/31/2022	
Total Attachments: 6		
source=X23034AssignmentLoxotoPetra#page1.tif		
source=X23034AssignmentLoxotoPetra#page2.tif		
source=X23034AssignmentLillytoPetra#page1.tif		

source=X23034AssignmentLillytoPetra#page2.tif
source=X23034AssignmentSchrodingerLLCtoPetra#page1.tif
source=X23034AssignmentSchrodingerLLCtoPetra#page2.tif

ASSIGNMENT

WHEREAS, LOXO ONCOLOGY, INC., a subsidiary of Eli Lilly and Company, having its principal place of business at Lilly Corporate Center, Indianapolis, IN 46285 and a correspondence address of c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 by virtue of an assignment between Erin Danielle ANDERSON, Sean Douglas ARONOW, Xiaohong CHEN, Surendra DAWADI, Thomas Combs IRVIN, Edward A KESICKI, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Gerit Maria POTOTSCHNIG, Hua-Yu WANG, Michael Brian WELCH, Tien WIDJAJA, and LOXO ONCOLOGY, INC., is the Assignee of the right, title and interest in an invention that is the subject of a patent application ("Application") which is entitled **ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE**, for filing:

☒ in the United States Patent and Trademark Office on 05/26/2022 and accorded Serial Number 17/825680

☐ in the _____ on _____ and accorded Serial Number _____,

☐ in the Spanish Patent Office as a European Application on _____ and accorded Serial Number _____,

☒ as an international application under the Patent Cooperation Treaty ("PCT"), with United States Patent and Trademark Office acting as Receiving Office on 05/26/2022 and accorded Serial Number PCT/US2022/031112

☐ as an international application under the Patent Cooperation Treaty ("PCT"), with The State Intellectual Property Office (SIPO) of China acting as Receiving Office on _____ and accorded Serial Number _____,

both of which claim the benefit of priority applications Serial Number 63/193917, filed May 27, 2021, Serial Number 63/227493, filed July 30, 2021, Serial Number 63/250592, filed September 30, 2021, and Serial Number 63/253352, filed October 7, 2021.

I hereby give permission to insert above the serial number(s) and filing date(s) for the application when known.

WHEREAS, PETRA PHARMA CORPORATION ("ASSIGNEE"), having a place of business at **450 E 29TH ST., SUITE 506, NEW YORK, NY 10016** wishes to acquire the entire right, title and interest in and to all invention disclosed in such Application, and in, to and under any Letters Patent which may be obtained to said invention; AND WHEREAS, accordingly the parties hereto are executing this Deed of assignment to record in writing the terms and conditions of their understanding.

NOW, THEREFORE, pursuant to an agreement between ASSIGNEE and LOXO ONCOLOGY, INC., or other good and valuable consideration, the receipt of which is hereby acknowledged, LOXO ONCOLOGY, INC. hereby sells, assigns, transfers and sets over unto ASSIGNEE, its successors and assigns LOXO ONCOLOGY, INC.'s entire right, title and interest in, to and under the Application, including all priority rights for other countries arising

therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by the ASSIGNEE for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by LOXO ONCOLOGY, INC. had this Assignment and sale to ASSIGNEE not been made.

LOXO ONCOLOGY, INC. authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any foreign equivalent thereof, to issue any such Letters Patent which may be granted on the Application to ASSIGNEE as assignee of the entire right, title and interest therein and thereto.

For ASSIGNEE and its legal representative, LOXO ONCOLOGY, INC. covenants and agrees that LOXO ONCOLOGY, INC. has not granted to any others any license to make, use or sell any of such inventions, that LOXO ONCOLOGY, INC.'s right, title and interest in such inventions has not been encumbered, that LOXO ONCOLOGY, INC. has good right and title to sell and assign the same, and that LOXO ONCOLOGY, INC. will not execute any instrument in conflict therewith.

IN WITNESS WHEREOF I have executed this assignment on the date indicated below.




Authorized Representative for
LOXO ONCOLOGY, INC.

Printed Name Tonya L. Combs

Title Vice President-Deputy General Patent Counsel

Date MAY 25, 2022

PETRA PHARMA CORPORATION, the assignee, hereby accepts the assignment from LOXO ONCOLOGY, INC. without any restrictions, and with all rights and obligations derived therefrom. Accepted as of the date above.



Authorized Representative for
PETRA PHARMA CORPORATION

Printed Name Joseph M. Fletcher

Title Sr. Director-Patent Counsel

Date May 25, 2022

ASSIGNMENT

WHEREAS, ELI LILLY AND COMPANY, having its principal place of business at Lilly Corporate Center, Indianapolis, IN 46285, by virtue of an assignment between Johnathan Alexander MCLEAN and Eli Lilly and Company, is the Assignee of the right, title and interest in an invention that is the subject of a patent application ("Application") which is entitled **ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE**, for filing:

☒ in the United States Patent and Trademark Office on 05/26/2022 and accorded Serial Number 17/825680

☐ in the _____ on _____ and accorded Serial Number _____,

☐ in the Spanish Patent Office as a European Application on _____ and accorded Serial Number _____,

☒ as an international application under the Patent Cooperation Treaty ("PCT"), with United States Patent and Trademark Office acting as Receiving Office on 05/26/2022 and accorded Serial Number PCT/US2022/031112

☐ as an international application under the Patent Cooperation Treaty ("PCT"), with The State Intellectual Property Office (SIPO) of China acting as Receiving Office on _____ and accorded Serial Number _____,

both of which claim the benefit of priority applications Serial Number 63/193917, filed May 27, 2021, Serial Number 63/227493, filed July 30, 2021, Serial Number 63/250592, filed September 30, 2021, and Serial Number 63/253352, filed October 7, 2021.

I hereby give permission to insert above the serial number(s) and filing date(s) for the application when known.

WHEREAS, PETRA PHARMA CORPORATION, a subsidiary of Eli Lilly and Company, having its principal place of business at **450 E 29TH ST., SUITE 506, NEW YORK, NY 10016** wishes to acquire the entire right, title and interest in and to all invention disclosed in such Application, and in, to and under any Letters Patent which may be obtained to said invention; AND WHEREAS, accordingly the parties hereto are executing this Deed of assignment to record in writing the terms and conditions of their understanding.

NOW, THEREFORE, pursuant an agreement between ASSIGNEE and ELI LILLY AND COMPANY, or other good and valuable consideration, the receipt of which is hereby acknowledged, ELI LILLY AND COMPANY hereby sells, assigns, transfers and sets over unto ASSIGNEE, its successors and assigns ELI LILLY AND COMPANY's entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the

Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by the ASSIGNEE for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by ELI LILLY AND COMPANY had this Assignment and sale to ASSIGNEE not been made.

ELI LILLY AND COMPANY authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any foreign equivalent thereof, to issue any such Letters Patent which may be granted on the Application to ASSIGNEE as assignee of the entire right, title and interest therein and thereto.

For ASSIGNEE and its legal representative, ELI LILLY AND COMPANY covenants and agrees that ELI LILLY AND COMPANY has not granted to any others any license to make, use or sell any of such inventions, that ELI LILLY AND COMPANY's right, title and interest in such inventions has not been encumbered, that ELI LILLY AND COMPANY has good right and title to sell and assign the same, and that ELI LILLY AND COMPANY will not execute any instrument in conflict therewith.


IN WITNESS WHEREOF I have executed this assignment on the date indicated below.



Authorized Representative for
ELI LILLY AND COMPANY

Printed Name Tonya L. Combs
Title Vice President-Deputy General Patent Counsel
Date MAY 25, 2022

PETRA PHARMA CORPORATION, the assignee, hereby accepts the assignment from ELI LILLY AND COMPANY without any restrictions, and with all rights and obligations derived therefrom. Accepted as of the date above.



Authorized Representative for
PETRA PHARMA CORPORATION
Printed Name Joseph M. Fletcher
Title Sr. Director-Patent Counsel
Date May 25, 2022

ASSIGNMENT

WHEREAS, Schrodinger, L.L.C., 1540 Broadway, 24th Floor, New York, NY 10036 by virtue of an assignment between Schrodinger, Inc. and **Schrodinger, L.L.C.**, is the Assignee of the right, title and interest in an invention that is the subject of a patent application ("Application") which is entitled **ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE**, for filing:

☒ in the United States Patent and Trademark Office on 05/26/2022 and accorded Serial Number 17/825680,

☐ in the _____ on _____ and accorded Serial Number _____,

☐ in the Spanish Patent Office as a European Application on _____ and accorded Serial Number _____,

☒ as an international application under the Patent Cooperation Treaty ("PCT"), with United States Patent and Trademark Office acting as Receiving Office on 05/26/2022 and accorded Serial Number PCT/US2022/031112

☐ as an international application under the Patent Cooperation Treaty ("PCT"), with The State Intellectual Property Office (SIPO) of China acting as Receiving Office on _____ and accorded Serial Number _____,

Which claims the benefit of priority applications Serial Number 63/193917, filed May 27, 2021, Serial Number 63/227493, filed July 30, 2021, Serial Number 63/250592, filed September 30, 2021, and Serial Number 63/253352, filed October 7, 2021.

I hereby give permission to insert above the serial number(s) and filing date(s) for the application when known.

WHEREAS, PETRA PHARMA CORPORATION ("ASSIGNEE"), having a place of business at **450 E 29TH ST., SUITE 506, NEW YORK, NY 10016** wishes to acquire the entire right, title and interest in and to all invention disclosed in such Application, and in, to and under any Letters Patent which may be obtained to said invention; AND WHEREAS, accordingly the parties hereto are executing this Deed of assignment to record in writing the terms and conditions of their understanding.

NOW, THEREFORE, pursuant an agreement between ASSIGNEE and **SCHRODINGER, L.L.C.**, or other good and valuable consideration, the receipt of which is hereby acknowledged, **SCHRODINGER, L.L.C.** hereby sells, assigns, transfers and sets over unto ASSIGNEE, its successors and assigns **SCHRODINGER, L.L.C.**'s entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention,

certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by the ASSIGNEE for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by **SCHRODINGER, L.L.C.** had this Assignment and sale to ASSIGNEE not been made.

SCHRODINGER, L.L.C. authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any foreign equivalent thereof, to issue any such Letters Patent which may be granted on the Application to ASSIGNEE as assignee of the entire right, title and interest therein and thereto.

For ASSIGNEE and its legal representative, **SCHRODINGER, L.L.C.** covenants and agrees that **SCHRODINGER, L.L.C.** has not granted to any others any license to make, use or sell any of such inventions, that **SCHRODINGER, L.L.C.**'s right, title and interest in such inventions has not been encumbered, that **SCHRODINGER, L.L.C.** has good right and title to sell and assign the same, and that **SCHRODINGER, L.L.C.** will not execute any instrument in conflict therewith.

IN WITNESS WHEREOF I have executed this assignment on the date indicated below.

/ DocuSigned by: *Ramy Farid* /
Authorized Representative for
SCHRODINGER, L.L.C.
Printed Name Ramy Farid
Title President & CEO
Date May 24, 2022

PETRA PHARMA CORPORATION, the assignee, hereby accepts the assignment from **SCHRODINGER, L.L.C.** without any restrictions, and with all rights and obligations derived therefrom. Accepted as of the date above.

/Joseph M Pletcher/
Authorized Representative for
PETRA PHARMA CORPORATION
Printed Name Joseph M. Pletcher
Title Sr. Director-Patent Counsel
Date May 25, 2022